Dr. Bilusic explains the evolution of immunotherapy in prostate cancer

Dr. Marijo Bilusic, MD, PhD, discusses the story of immunotherapy in prostate cancer, from the initial revolutionary breakthrough with sipuleucel-T (Provenge), through the research struggles with immune checkpoint inhibitors, to emerging strategies, such as vaccines, for converting immunologically “cold” tumors to immunologically “hot” tumors.

Dr. Bilusic is a medical oncologist and GU Site Disease Group Lead, Sylvester Comprehensive Cancer Center, Miami Florida. Prior to joining starting at Sylvester in 2021, he was an associate research physician at the NCI Medical Oncology Service/Genitourinary Malignancy Branch. Also at the NCI, he served as program director of the NIH Hematology Oncology Fellowship Program.